Skip to main content
Figure 5 | BMC Biotechnology

Figure 5

From: Site-directed in vitro immunization leads to a complete human monoclonal IgG4λ that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands

Figure 5

Binding of γ4λhuCD152 and CD80/CD86 agonists to human CD152 are not mutually exclusive. Panel A indicates the ligand competition assays that test the ability of monoclonal γ4λhuCD152 (solid line) and BNI3 (dashed line) anti-CD152 to compete for the CD80/CD86 and CD152 interactions. Biotinylated CD80-muIg or CD86-muIg plus indicated increasing concentrations of the mAbs (10-3-10 μg/mL) were incubated in microtiter wells coated with purified CD152-muIg. Bound CD80/CD86 was detected with avidin-peroxidase conjugate and a peroxidase substrate. The data shown are representative of three experiments. Panel B illustrates the determination of in situ CD152 expression before and after PHA/PMA stimulation. Paraformaldehyde-fixed cells were first labeled with PE-anti-CD3 and BNI3 or γ4λhuCD152, and then incubated with FITC-conjugated anti-mouse IgG2a or anti-human IgGs, respectively. The percentage of each stained population after stimulation is denoted.

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us